Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Immunol. Jul 27, 2014; 4(2): 116-121
Published online Jul 27, 2014. doi: 10.5411/wji.v4.i2.116
Published online Jul 27, 2014. doi: 10.5411/wji.v4.i2.116
Targeting TLR4/MAPKs signaling pathway: A better option for therapeutic inhibition of atherosclerosis
Janeesh Plakkal Ayyappan, Annie Abraham, Department of Biochemistry, School of Life sciences, University of Kerala, Kariavattom Campus, Thiruvananthapuram 695 581, Kerala, India
Author contributions: All authors contributed to this paper.
Supported by University of Kerala, India for the study
Correspondence to: Dr. Annie Abraham, Director, Professor of Biochemistry, Department of Biochemistry, School of Life sciences, University of Kerala, Kariavattom Campus, Thiruvananthapuram 695 581, Kerala, India. annieab2001@gmail.com
Telephone: +91-471-2308078 Fax: +91-471-2308614
Received: March 28, 2014
Revised: May 10, 2014
Accepted: June 27, 2014
Published online: July 27, 2014
Revised: May 10, 2014
Accepted: June 27, 2014
Published online: July 27, 2014
Core Tip
Core tip: The inhibition of atherosclerosis is one of primary target for the therapeutics of cardiovascular diseases, which is the eminent health problem worldwide. The important function of toll-like receptor 4 (TLR4) in the activation and progression of atherosclerosis is justified here. The TLR4 in turn activates the mitogen activated protein kinases (MAPKs) and nuclear factor kappa-light-chain-enhancer of activated B cells which are responsible for most of the inflammatory events. Hence, therapeutic inhibition of TLR4/MAPKs signaling pathway is one of the best method of inhibiting atherosclerosis.